A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV

Abstract excerpt

Therapeutic development is critical for preventing and treating continual MERS-CoV infections in humans and camels. Because of their small size, nanobodies (Nbs) have advantages as antiviral therapeutics (e.g., high expression yield and robustness for storage and transportation) and also potential limitations (e.g., low antigen-binding affinity and fast renal clearance). Here, we have developed novel Nbs that...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Monoclonal and Polyclonal Antibodies Research
• Share to SARS-CoV-2 and COVID-19 Research
• Share to Viral gastroenteritis research and epidemiology